TNFSF13B and diabetes mellitus: Moreover, the pathogenic role of B cells is supported by prevention or suppression of diabetes via therapeutic treatments that broadly target B cells in NOD mice [i.e., mAbs to CD20, CD22, and BlyS/BAFF; reviewed in (19–21)] and in human clinical trials [i.e., anti-CD20 mAb, rituximab (22–24)].